USVI Response Measures

1. Prevent, delay, and mitigate transmission: Develop screening at ports of entry; provide best practices and guidance to organizations to reduce transmission; develop strategies for vulnerable populations.

2. Conduct surveillance: Inform the response based on epidemiologic data; liaise with healthcare sector to identify cases and define clinical and transmission characteristics; operate epi hotline; track persons under investigation; perform contact tracing of cases; conduct follow-up sampling of cases; coordinate with lab.

3. Provide public health & safety messaging: Develop communication strategy; build capacity with partners; provide daily.

4. Provide medical guidance: Provide Infection Prevention and Control guidance related to healthcare personnel and health systems; provide guidance to clinicians on treatment and management of patients.

5. Conduct lab testing: Build laboratory testing capacity for VIDO; explore external lab capacity; manage specimen collection and supplies.

6. Coordinate medical surge capacity: Assess resource needs and inventory resources (equipment, staff); develop a health and medical staffing strategy; prepare resource requests for material aid and staff (federal partner, EMAC, etc); develop resource management, utilization, and prioritization plan.

Testing Summary

<table>
<thead>
<tr>
<th>Date</th>
<th>Total tested</th>
<th>Tested positive</th>
<th>Tested negative</th>
<th>Pending tests</th>
<th>Change since 25-Apr</th>
</tr>
</thead>
<tbody>
<tr>
<td>26-Apr</td>
<td>780</td>
<td>59</td>
<td>716</td>
<td>5</td>
<td>+4</td>
</tr>
<tr>
<td>25-Apr</td>
<td>776</td>
<td>57</td>
<td>700</td>
<td>19</td>
<td>+2</td>
</tr>
<tr>
<td>Positive</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>Negative</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>Pending</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
</tbody>
</table>

Test result among males and females

- Males: n=22
- Females: n=264
- Unknown: n=34

Test result by age group

- Median age among cases = 49 years
- Test positive
  - 65+: 9%
  - 50-64: 8%
  - 18-49: 7%
  - 0-17: 7%

Sample collection dates of persons under investigation for COVID-19 in the U.S. Virgin Islands

- Illnesses that started during this time may not yet be reported

Contact Numbers: Hotline

Informational Hotline (non-medical 8am-8pm)
Hosted by VITEMA: 340-715-6843
Potential PUUs only 8am-10pm
STX: (340) 712-6299
STT/STJ: (340) 776-1519

Calls volume to the hotline

<table>
<thead>
<tr>
<th>Date</th>
<th>Total Calls</th>
<th>Change since 25-Apr</th>
</tr>
</thead>
<tbody>
<tr>
<td>26-Apr</td>
<td>10</td>
<td>▲ 4</td>
</tr>
<tr>
<td>25-Apr</td>
<td>6</td>
<td></td>
</tr>
</tbody>
</table>

Calls completed from March 5-Apr 26, 2020

- 1,703 total calls, average of 32 per day
Confirmed COVID-19 cases in the U.S. Virgin Islands, N=59

**St. Croix**
- **Current status of cases**
  - Active: 4
  - Recovered: 51
  - Fatality: 4
- **Risk factors for transmission**
  - Community transmission: 18
  - Close contact: 19
  - Travel: 22
  - Under investigation: 0

**St. Thomas**
- **Clinical symptoms**
  - Cough: 42 (71%)
  - Fever*: 37 (63%)
  - Shortness of breath: 21 (36%)
  *Subjective fever or measured temp ≥100.4°F
- **26-Apr | 25-Apr | Change since 25-Apr**
  - Positive: 20 | 19 | ▲ 1
  - Negative: 370 | 365 | ▲ 5
  - Pending: 4 | 7 | ▼ -3
- **Risk factors for transmission**
  - Community transmission: 3
  - Close contact: 5
  - Travel: 12
  - Under investigation: 0

**St. John**
- **26-Apr | 25-Apr | Change since 25-Apr**
  - Positive: 2 | 2 | ▼ 0
  - Negative: 24 | 24 | ▼ 0
  - Pending: 0 | 0 | ▼ 0
- **Risk factors for transmission**
  - Community transmission: 0
  - Close contact: 0
  - Travel: 2
  - Under investigation: 0

---

**All data is provisional**